Table 1 Demographic and clinic data for all patients requiring treatment with intraarticular steroids (IAS) or systemic treatment
Category | Total n (% or mean) | IAS n (%) | Systemic Treatment n (%) | p-value | |
|---|---|---|---|---|---|
All | 185 (100%) | 46 (25%) | 139 (75%) | ||
Sex | Male | 46 (25%) | 12 (26%) | 34 (24%) | 0.82 |
Female | 139 (75%) | 34 (74%) | 105 (76%) | ||
Age at Diagnosis (years) | 7.3 (4.7) | 7.1 (4.7) | 7.4 (4.7) | 0.72 | |
Race* | White | 160 (86%) | 42 (91%) | 118 (85%) | 0.78 |
Black, African American, African, or Afro-Caribbean | 5 (3%) | 2 (4%) | 3 (2%) | ||
Hispanic, Latino, or Spanish origin | 14 (8%) | 3 (7%) | 11 (8%) | ||
Asian | 6 (3%) | 0 (0%) | 6 (4%) | ||
Middle Eastern/North African | 1 (1%) | 1 (2%) | 0 (0%) | ||
Native American, American Indian or Alaskan Native | 1 (1%) | 0 (0%) | 1 (1%) | ||
Native Hawaiian or Other Pacific Islander | 1 (1%) | 0 (0%) | 1 (1%) | ||
JIA subtype | Oligoarticular | 77 (42%) | 27 (59%) | 50 (36%) | 0.07** |
Polyarticular | 78 (42%) | 14 (30%) | 64 (46%) | ||
Psoriatic | 15 (8%) | 4 (9%) | 11 (8%) | ||
ERA | 12 (6%) | 1 (2%) | 11 (8%) | ||
Undifferentiated | 3 (2%) | 0 (0%) | 3 (2%) | ||
ANA | Negative | 98 (53%) | 21 (46%) | 77 (55%) | 0.25 |
Positive | 87 (47%) | 25 (54%) | 62 (45%) | ||
RF | Negative | 178 (96%) | 46 (100%) | 132 (95%) | 0.2 |
Positive | 7 (4%) | 0 (0%) | 7 (5%) | ||
CCP | Negative | 178 (96%) | 45 (98%) | 133 (96%) | 0.68 |
Positive | 7 (4%) | 1 (2%) | 6 (4%) | ||
B27 | Negative | 171 (92%) | 42 (91%) | 129 (93%) | 0.75 |
Positive | 14 (8%) | 4 (9%) | 10 (7%) | ||
Uveitis | No | 159 (86%) | 37 (80%) | 122 (88%) | 0.21 |
Yes | 26 (14%) | 9 (20%) | 17 (12%) | ||
Methotrexate | No | 8 (4%) | 3 (7%) | 5 (4%) | 0.41 |
Yes | 177 (96%) | 43 (93%) | 134 (96%) | ||
Biologic | No | 49 (26%) | 22 (48%) | 27 (19%) | < 0.001 |
Yes | 136 (74%) | 24 (52%) | 112 (81%) |